Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cubist Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates-Conference Call


Wednesday, 23 Jan 2013 10:00pm EST 

Cubist Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues to be $1.000-$1.045 billion. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.035 billion for fiscal 2013.